Medtronic and Lifetech Scientific expand their deal to co-produce pacemakers for the Chinese market.
Medtronic agrees to pay $2.8 million to close the books on a multi-state and federal lawsuit accusing the company of illegally soliciting insulin pump patients to replace their devices.
Federal and state regulators agreed to a $2.8 million settlement with medtech titan Medtronic (NYSE:MDT) to close the books on a years-old concern over insulin infusion pumps.
Minnesota medical device maker Medtronic estimates that China could soon account for 20% of the company's global diabetes revenues, according to a local report.
MASSDEVICE ON CALL — Medtronic (NYSE:MDT) is looking to significantly boost its reach in China, country with "the world's biggest diabetes epidemic," according to a local report.
A Medtronic shareholder is reportedly looking to block the pending, $43 billion merger with Covidien, arguing that the deal leaves stockowners on the hook for significant tax liabilities.
Intersect ENT prices its initial public offering at $11 per share, the low end of its predicted range, hoping to raise $55 million when XENT shares hit the NASDAQ exchange today.
Intersect ENT said today that it's shares should hit the NASDAQ exchange at $11 apiece, the low end of the range, for expected proceeds of $55 million.
At that price, Intersect would command a market capitalization of roughly $267 million.
Here's a look at some of the top Wall Street stories for medical device companies this week: Abbott CEO defends inversions amid corporate exodus furor; Medtronic fights tax dodging rhetoric in Covidien merger; Allergan cuts 1,500 jobs, faces SEC complaint; A countdown to failure for Valeant's hostile $53B Allergan takeover; GE Healthcare idles for another quarter
Medtech titan Medtronic has developed 175 iOS apps for internal use by its employees, according to Apple.